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Abstract:	
	
Human	immunodeficiency	virus	(HIV)	poses	a	large	burden	on	global	health.	Through	the	
development	of	highly	active	antiretroviral	therapy	(HAART),	HIV	infected	individuals	are	living	
longer	lives	with	undetectable	viral	loads.	In	spite	of	the	advancement	in	treatment,	the	
incidence	of	new	HIV	infections	continues	to	increase.	Emphasis	has	now	shifted	to	
preventative	strategies	including	intravaginal	rings	(IVR).		The	objective	of	this	study	was	to	
manufacture	IVRs	with	10%w/w	of	rilpivirine	(RPV)	or	dolutegravir	(DTG).	Based	on	success	of	
manufacturing,	the	next	steps	were	in	vitro	and	in	vivo	release	studies	with	the	goal	to	have	
sustained	release	for	a	minimum	of	30	days.		Both	in	vitro	release	studies	surpassed	30	days	of	
zero	order	release.	RPV	achieved	100%	release	and	DGT	achieved	60%	release.	In	vivo	mice	
pharmacokinetics	studies	were	promising	since	the	concentrations	of	RPV	and	DTG	were	above	
the	IC90	locally	for	the	duration	of	the	28	day	study.	Plasma	concentration	of	RPV	did	not	reach	
the	IC90	at	any	point	during	the	study.		Overall,	RPV	and	DTG	are	possible	ARTs	to	be	further	
evaluated	for	the	prevention	of	HIV	using	an	IVR.	Additional	studies	are	needed	to	determine	
the	efficacy	and	the	possibility	of	combination	IVRs.		
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Introduction:	
	
Human	immunodeficiency	virus	(HIV)	poses	a	large	burden	on	global	health.	Worldwide	in	
2015,	36.7	million	people	were	living	with	HIV	and	approximately	2.1	million	people	were	newly	
infected.1	Current	treatment	available	for	HIV	infected	individuals	consists	of	combining	
antiretroviral	drugs	with	differing	mechanisms	of	action,	which	is	often	referred	to	as	highly	
active	antiretroviral	therapy	(HAART).	Despite	the	advancement	and	success	of	HAART	in	
decreasing	morbidity	and	morality	of	individuals	with	HIV,	HAART	has	been	insufficient	to	curb	
the	pandemic	causing	a	shift	to	prevention	strategies.		
Current	preventative	strategies	consist	of	behavioral	interventions,	oral	antiretroviral	(ARV)	
pre-exposure	prophylaxis	(PrEP)	and	topical	microbicides.	The	only	FDA	approved	PrEP	therapy	
is	truvada,	emtricitabine	and	tenofovir	disoproxil	fumarate.2	Truvada	has	shown	efficacy	in	
prevention	of	HIV	for	individuals	at	high	risk,	such	as	men	who	have	sex	with	men	or	
serodiscordant	couples.	3,4,5	Drawbacks	to	truvada	are	the	importance	of	adherence	and	
systemic	exposure	to	ARVs	in	HIV	negative	individuals.	The	iPrEx	study	showed	a	44%	reduction	
in	HIV	infection	rate	in	HIV	negative	gay	men	who	received	daily	truvada	compared	to	placebo.5	
In	a	subanalysis	within	the	iPrEx	trial,	the	adherence	rate	to	the	once	daily	regimen	was	51%.	
The	investigators	calculated	the	efficacy	would	have	been	at	least	92%	if	the	adherence	had	
been	100%.		
In	order	to	avoid	adherence	issues,	other	routes	of	administration	are	available.	Sustained	
delivery	to	the	vaginal	tract	provides	an	alternative	approach	to	oral	preventative	therapy.	
Benefits	of	intravaginal	delivery	are	numerous	from	low	systemic	exposure,	avoiding	
gastrointestinal	and	first	pass	metabolism,	and	large	surface	area	with	a	rich	blood	supply.6	
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Additionally,	sterility	is	not	required	and	patients	can	easily	self-administer.	An	example	of	an	
appropriate	delivery	device	is	an	intravaginal	ring	(IVR)	because	IVRs	are	designed	to	deliver	
drug	in	a	controlled,	sustained	release	fashion.	IVRs	do	not	require	daily	administration	thus	
decreasing	the	pill	burden	of	the	individual.	IVRs	containing	contraceptive	and	hormone	
replacement	therapy	are	commercially	available	and	well	tolerated.		
The	objective	of	the	study	was	to	develop	and	manufacture	IVRs	containing	at	least	10%	weight	
by	weight	ARV.	Based	on	the	success	of	the	first	objective,	the	evaluation	of	the	IVRs	stability	
and	release	in	vivo	would	be	completed.		
	
Methods:	
	
IVR	composition:	
The	active	ARVs	used	were	rilprivirine	(RPV),	a	non-nucleoside	reverse	transcriptase	inhibitor,	
and	Dolutegravir	(DTG),	an	integrase	inhibitor.	RPV	and	DTG	were	chosen	because	of	different	
mechanisms	of	action,	relevance	as	viable	clinical	and	commercial	products	and	the	lack	of	
pharmacokinetic	interactions.7	The	polymer	base	used	for	the	IVRs	was	poly(ethylene-co-vinyl	
acetate)	(EVA).	EVA	is	easy	to	manufacture	and	hydrophobic	in	nature	which	is	preferred	for	
sustained	release	profiles	of	RPV	and	DTG.		Manufacturing	of	the	IVRs	consisted	of	melting	EVA	
and	adding	small	quantities	of	active	ingredient	at	a	time	to	achieve	uniform	dissolution	and	
achieve	10%	w/w	of	active	drug.	While	the	polymer	was	still	malleable	and	warm,	a	mold	was	
used	to	form	4mm	outer	diameter	with	1mm	cross-section	IVR.		
	
In	vitro	release	studies:	
IVRs	were	submerged	and	fixed	in	place	in	one	of	two	buffer	solutions,	50%	v/v	isopropyl	
alcohol	or	25mM	sodium	acetate	(pH	4.2)	and	2%	w/w	solutol.	Sodium	acetate	with	solutol	at	a	
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pH	around	4	simulated	the	intravaginal	environment.		The	IVRs	were	submerged	at	37°C	under	
sink	conditions	for	a	minimum	of	30	days.	During	various	time	points	throughout	the	30	days,	
1mL	samples	were	taken	and	buffer	volume	was	replaced.	Samples	were	taken	more	frequently	
within	the	first	24	hours	in	order	to	capture	any	burst	release,	followed	by	daily	sampling	for	
the	first	week	and	once	a	week	thereafter.		Drug	concentrations	were	quantified	by	HPLC.		
		
In	vivo	pharmacokinetics	studies:	
BALB/c	mice	were	used	as	the	mouse	model	for	the	in	vivo	evaluation	of	the	IVRs	(N	=3	for	each	
for	RPV	and	DTG).	Due	to	the	flexible	nature	of	the	mice,	the	IVRs	must	be	surgically	implanted	
into	the	mice	vaginal	cavities.	Placebo	IVRs	consisting	of	only	EVA	were	produced	and	used	to	
anchor	the	active	IVR	in	place	(Figure	1).	The	surgical	procedure	was	modified	from Saltzman	et	
al.8	The	method	had	been	validated	and	used	for	the	past	three	years	in	the	lab	prior	to	this	
experiment.	The	animal	facility	core	at	University	of	North	Carolina	performed	the	procedure.	
Plasma	and	vaginal	lavage	samples	were	taken	post	implantation	day	1,	3,	7,	14,	21	and	28	
(Figure	2).	Where	as	cervical/vaginal	tissue	(CVT)	samples	were	taken	at	day	7,	14	and	28	
because	the	mouse	had	to	be	sacrificed	in	order	to	obtain	the	CVT	samples.			
Figure	1:	Drawing	of	the	female	mouse	reproductive	system	and	the	approximate	placement	of	
the	active	IVR	and	the	anchoring	placebo	IVR.8		
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Figure	2:	Schematic	diagram	of	sample	collection	in	the	BALB/c	mice.	
	
	
	
	
	
	
	
	
	
Data	analysis:	
	
Results:	
	
in	vitro	
The	in	vitro	release	studies	surpassed	the	original	30-day	requirement.	As	the	release	study	
progressed,	both	drugs	were	still	being	released	therefore	decided	to	continue	collecting	
samples.	As	seen	in	Figure	3A/3B,	RPV	achieved	a	10%	burst	release	in	the	first	24	hours	with	a	
sustained	release	of	3.3μg/day.	DTG’s	burst	release	was	about	20%	within	the	first	24	hours	
with	a	sustained	release	of	2.7μg/day.	Both	reached	steady	state	and	maintained	zero	order	
kinetics.		
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Figure	3A/3B:		
3A:	in	vitro	release	of	RPV	in	50%	v/v	isopropyl	alcohol	
	 	
3B:	in	vitro	release	of	DTG	in	50%	v/v	isopropyl	alcohol	
	 	
	
in	vivo		
Among	the	three	IVRs	per	active	drug	used	for	the	in	vivo	study,	the	amount	of	DTG	ranged	
from	1.0-1.12mg	and	RPV	ranged	from	1.1-1.15mg.	The	IC90	for	RPV	and	DTG	were	defined	as	
12ng/ml	and	16.8ng/ml,	respectfully.		Over	the	28	days,	mouse	vaginal	lavage	and	CVT	
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concentrations	for	both	study	drugs	stayed	above	the	IC90	(Figure	4A/4B).	DTG	sustained	
plasma	concentrations	above	the	IC90	for	the	duration	of	the	study.	However,	RPV	plasma	
concentrations	never	reached	the	IC90.		
Figure	4A/4B:	in	vivo	release	studies	
	
2A.	RPV	plasma,	cervical	tissue	and	vaginal	lavage	concentrations	in	BALB/c	mice	over	28	days.	
	
	
	
2B:	DTG	plasma,	cervical	tissue	and	vaginal	lavage	concentrations	in	BALB/c	mice	over	28	days.	
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Discussion:	
During	the	in	vitro	release	studies,	RPV	rings	were	manufactured	and	release	study	was	set	up	
prior	to	the	manufacturing	of	DTG	rings	hence	why	the	study	is	longer	than	DTG’s	study.	The	
total	amount	of	RPV	was	released	after	about	1	year	whereas	DTG’s	release	plateaued.	A	
possible	reason	for	the	plateau	is	the	loss	of	sink	conditions	despite	the	addition	of	1ml	buffer	
following	sampling.	Another	difference	is	due	to	release	profiles	are	drug	specific.	If	compared	
side	by	side	at	day	225,	85%	of	RPV	and	60%	of	DTG	had	been	released	from	the	respected	
IVRs.	Regardless	of	the	differences	seen	in	intro,	the	release	profiles	of	both	IVRs	were	
promising	and	lead	to	in	vivo	testing.	
The	evaluation	of	RPV	and	DTG	containing	IVRs	in	vivo	was	necessary	to	determine	the	stability	
and	release	profile	in	the	mouse	model	over	an	extended	period	of	time.	The	BALB/c	mouse	
model	was	chosen	due	to	the	cost	and	availability.	Pharmacokinetics	is	assumed	to	be	
consistent	throughout	mice	regardless	of	immune	system	function.	Both	had	sustained	release	
of	drug	for	the	whole	28	days.			Concentration	of	drug	was	above	the	IC90	for	both	study	drugs	
in	the	vaginal	lavage	and	vaginal	tissue	for	the	study	in	its	entirety.	Drug	levels	locally	were	high	
enough	to	potentially	protect	against	the	transmission	of	HIV	vaginally.	This	is	promising	for	the	
project	moving	forward	towards	the	use	of	combination	ART	IVRs.		
Future	studies	are	needed	to	evaluate	the	efficacy	of	ART	IVRs	for	the	prevention	of	HIV	
transmission.	Next	steps	include	testing	efficacy	in	humanized	bone	marrow/liver/thymus	(BLT)	
mice.	Mice	in	general	are	incapable	of	contracting	HIV,	therefore	a	specialized	BLT	mouse	
model	is	necessary.	An	issue	with	the	current	protocol	is	the	invasive	procedure	needed	to	
implant	the	IVR.	The	method	involves	an	abdominal	incision	and	vascular	trauma,	which	in	itself	
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causes	an	increased	risk	of	contracting	HIV	when	challenged.	Therefore	an	appropriate	amount	
of	time	must	be	given	for	the	mouse	to	heal,	which	differs	from	how	a	female	would	be	using	
the	product.		
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